Group 1 - The A-share market shows a strong growth style, with notable performances in the pharmaceutical and semiconductor sectors, where multiple related ETFs rose over 5% in a single day [1] - The Hong Kong pharmaceutical sector is performing strongly, with several ETFs in innovative drugs and medical devices increasing by over 6%, highlighting the attractiveness of the sector post-adjustment [4][5] - The semiconductor sector is also experiencing significant gains, with multiple ETFs in this field rising over 5%, indicating a robust market for semiconductor-related investments [6][7] Group 2 - In December 2025, the A500 and Sci-Tech bonds became major directions for capital inflow, with several ETFs in these categories seeing net inflows exceeding 100 billion yuan [2][8] - The total net inflow for all ETFs in the market reached 11,785.99 billion yuan in 2025, showcasing a strong interest in ETF investments [2] - Specific ETFs such as the FuGuo CSI Hong Kong Internet ETF and the HuaAn Gold ETF saw annual net inflows exceeding 400 billion yuan, indicating strong investor confidence in these funds [10] Group 3 - The Hong Kong market is expected to see a recovery in corporate earnings, particularly benefiting sectors like non-ferrous metals and competitive industry leaders in internet and consumption [10][11] - The anticipated decline in risk-free rates in Hong Kong may lead to improved liquidity, potentially enhancing valuations in the market [11] - Key investment focuses for 2026 are expected to include AI, new consumption, pharmaceuticals, and dividend stocks, reflecting evolving market trends [11]

01 1月5日，A股成长风格走强，医药与半导体板块表现亮眼，多只相关主题ETF单日涨超5%。此外，黄 金、有色、军工、港股消费等板块亦有不错表现。多只银行、石油、红利等主题ETF表现疲软。 02 2025年12月，A500、科创债成为资金涌入的重要方向，多只相关主题ETF当月净流入额超100亿元。纵 观整个2025年，富国中证港股通互联网ETF、华安黄金ETF、嘉实中证AAA科技创新公司债ETF、海富 通中证短融ETF年度净流入额超400亿元。Wind数据显示，2025年，全市场所有ETF净流入额合计达 11785.99亿元。 今日，医药板块行情火热。多只港股创新药ETF、医疗器械ETF等涨超6%，其中港股通医疗ETF富国 （159506）单日涨幅达7.13%。 | 港股医药板块表现强势 | | --- | | 代码 | 名称 | 现价(元) | 涨跌幅 (%) | | --- | --- | --- | --- | | 159506.SZ | 港股通医疗ETF富国 | 1.40 | 7.13 | | 159570.SZ | 港股通创新药ETF | 1.64 | 6.97 | | 562600.SH | 医疗 ...

Core Viewpoint - The A-share market has shown strong performance, achieving a 12-day consecutive rise and surpassing the 4000-point mark, marking the longest winning streak since 1993, driven by various sectors including AI and semiconductor stocks [1][11]. Market Performance - The A-share market's trading volume reached 2.5 trillion yuan, with significant gains across multiple sectors, including brain-computer interfaces, AI applications, commercial aerospace, memory chips, and innovative pharmaceuticals [1]. - The South Korean Composite Index rose approximately 3.4%, while the Nikkei 225 Index increased nearly 3%, with AI chip concepts leading the gains [1]. Sector Highlights - The semiconductor sector saw the China-Korea Semiconductor ETF rise by 8.45%, driven by news of Samsung and SK Hynix seeking a 70% price increase for server memory chips [1]. - Medical ETFs, including the Hong Kong Medical ETF and the Hong Kong Innovative Drug ETF, experienced significant increases of 7.13% and 6.97%, respectively, with medical device ETFs also performing well [1][2]. Fund Inflows - Various ETFs, including the Satellite ETF and the Robotics ETF, are expected to see net inflows of 690 million yuan and 340 million yuan, respectively, indicating strong investor interest [4]. - The overall sentiment in the A-share market is positive, with expectations of increased capital inflows [5]. Future Outlook - Goldman Sachs has recommended overweighting Chinese stocks, projecting annual returns of 15%-20% for the Chinese stock market in 2026-2027, driven by factors such as profit improvement, valuation recovery, policy support, and macro resilience [11][12]. - Key drivers for profit growth include manufacturing upgrades, AI application advantages, improved profit margins, and a structural increase in exports of high-value products [11].

旅游板块走低，两只旅游ETF跌1%。油气板块走低，能源化工ETF、石油天然气ETF分别跌1%和 0.63%。 （责任编辑：刘畅 ） 【免责声明】本文仅代表作者本人观点，与和讯网无关。和讯网站对文中陈述、观点判断保持中立，不对所包含内容 的准确性、可靠性或完整性提供任何明示或暗示的保证。请读者仅作参考，并请自行承担全部责任。邮箱： news_center@staff.hexun.com A股2026年开门红，上证指数放量收涨1.38%，重返4000点；创业板指大涨2.85%。沪深京三市成交 额25672亿元，较上日放量5015亿元。市场近4200股上涨。脑机接口、AI应用、商业航天、存储器、创 新药概念股掀涨停潮，保险股表现抢眼。海南自贸区、稳定币题材出现调整。 ETF方面，半导体产业链爆发，华泰柏瑞基金中韩半导体ETF飙涨8.46%。港股创新药板块强势反 攻，港股通医疗ETF富国、汇添富基金港股通创新药ETF和华夏基金医疗器械ETF分别涨7.13%、6.97% 和6.95%。游戏传媒板块表现亮眼，浦银安盛基金游戏传媒ETF涨6.22%， ...

上证报中国证券网讯 12月15日，ETF午间收盘涨跌不一，卫星ETF(159206)涨2.74%，航空航天 ETF(563380)涨2.37%，证券保险ETF(512070)涨2.35%，港股通医疗ETF富国(159506)跌2.89%，港股创 新药ETF基金(520700)跌2.85%，港股通创新药ETF(159570)跌2.73%。 上证报中国证券网讯 12月15日，ETF午间收盘涨跌不一，卫星ETF(159206)涨2.74%，航空航天 ETF(563380)涨2.37%，证券保险ETF(512070)涨2.35%，港股通医疗ETF富国(159506)跌2.89%，港股创 新药ETF基金(520700)跌2.85%，港股通创新药ETF(159570)跌2.73%。 来源：上海证券报·中国证券网 来源：上海证券报·中国证券网 ...

Core Points - The A-share market saw all three major indices rise in the morning session, with the Shanghai Composite Index up 0.08%, the Shenzhen Component Index up 0.39%, and the ChiNext Index up 0.47% [1] - The total trading volume in the Shanghai, Shenzhen, and Beijing markets reached 999.6 billion yuan, a decrease of 40.6 billion yuan compared to the previous day [1] - Over 3,500 stocks in the market experienced gains, indicating a broad-based rally [1] Sector Performance - CPO concept stocks surged, while local stocks in Fujian remained active; sectors such as superconductors, ultra-high voltage, 6G, and photovoltaic indices showed significant gains [1] - The banking, real estate, and pharmaceutical sectors faced declines, with the real estate sector leading the losses [1] - ETFs related to industrial and non-ferrous metals led the gains, with the Wanjia Fund's industrial non-ferrous ETF rising by 2.5% [1] - The electric grid equipment sector performed well, with multiple ETFs in this category rising by 2% [1] - The photovoltaic sector also saw a rise, with leading ETFs in this space increasing by 2% [1] - Real estate ETFs declined by 1.4%, reflecting the struggles in the real estate sector [1] - Japanese stocks fell, with the Tokyo Stock Exchange Index ETF down by 1.2% [1] - The innovative drug sector showed weakness, with ETFs in this category declining by 1% [1]

来源：视频滚动新闻 11月18日，港股通医疗ETF富国（159506）跌1.72%，成交额3.73亿元。当日份额增加1100.00万份，最 新份额为23.00亿份，近20个交易日份额增加5000.00万份。最新资产净值计算值为34.11亿元。港股通医 疗ETF富国（159506）业绩比较基准为恒生港股通创新药及医疗保健指数收益率(使用估值汇率折算)， 管理人为富国基金管理有限公司，基金经理为田希蒙，成立（2023-06-14）以来回报为48.33%，近一个 月回报为-0.70%。风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的 信息（包括但不限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构 成个人投资建议。 ...

Core Viewpoint - The Hong Kong stock market for innovative drugs is experiencing significant growth, with major companies like 3SBio and BeiGene seeing substantial stock price increases, which is positively impacting various ETFs related to innovative drugs and healthcare [1][6]. Group 1: Market Performance - 3SBio's stock rose over 7%, while BeiGene's increased by more than 6%, contributing to a rise of over 4% in several innovative drug ETFs [1]. - The top-performing ETFs include the Southern Hong Kong Stock Connect Innovative Drug ETF, which rose by 4.15%, and the Fortune Hong Kong Stock Connect Medical ETF, which increased by 4.08% [3]. Group 2: Company Performance - BeiGene reported a third-quarter revenue of 10.077 billion yuan, a year-on-year increase of 41.1%, and a net profit of 689 million yuan, marking a return to profitability [6]. - For the first three quarters, BeiGene's revenue reached 27.595 billion yuan, up 44.2%, with a net profit of 1.139 billion yuan, also indicating a turnaround [6]. Group 3: Industry Trends - The innovative drug sector is witnessing a fundamental improvement driven by policy support, performance realization, and accelerated international expansion [6][7]. - The introduction of a new "commercial insurance innovative drug catalog" in 2025 is expected to create new payment channels for high-priced innovative drugs, enhancing cash flow for pharmaceutical companies [6]. - The industry is transitioning from a "research investment phase" to a "commercialization phase," with many leading drug companies showing strong performance in their third-quarter reports [7]. Group 4: International Expansion - From January to October 2025, the total value of international licensing transactions for Chinese innovative drugs exceeded 100 billion USD, indicating a growing recognition of Chinese drug pipelines by multinational corporations [7][8]. - The increasing global competitiveness of Chinese pharmaceutical companies is being validated through successful international collaborations and licensing agreements [8].

Market Overview - The three major A-share indices collectively declined, with the Shanghai Composite Index down 0.24%, the Shenzhen Component Index down 1.07%, and the ChiNext Index down 1.58% [1] - The total trading volume in the Shanghai, Shenzhen, and Beijing markets reached 12,702 billion yuan, an increase of 22 billion yuan compared to the previous day [1] - Over 4,000 stocks in the market experienced declines [1] Sector Performance - The oil and gas extraction and services, insurance, brain-computer interface, banking, and influenza sectors saw the largest gains [1] - Conversely, the photovoltaic equipment, cultivated diamonds, controllable nuclear fusion, phosphorus chemical, battery, military equipment, and photolithography concept stocks faced the most significant declines [1] ETF Performance - The innovative drug sector rebounded across the board, with the S&P Biotechnology ETF, Hong Kong Stock Connect Innovative Drug ETF, and NASDAQ Biotechnology ETF rising by 3.87%, 2.94%, and 2.86% respectively [1] - The Hong Kong Stock Connect medical ETFs, including the Fidelity and Huatai-PineBridge Innovative Drug ETFs, both increased by 2.75% [1] - The petrochemical sector also saw a rebound, with the Harvest Fund S&P Oil and Gas ETF rising by 1.95% [1] Photovoltaic Sector - The photovoltaic sector experienced a significant downturn, with the Kexin New Energy ETF, Photovoltaic ETF Index Fund, and Kexin Board New Energy ETF dropping by 5.91%, 5.82%, and 5.68% respectively [2] - The power grid sector followed suit, with the power grid equipment ETF declining by 3.11% and the power grid ETF down by 2.87% [2]

Core Viewpoint - The Hong Kong stock market showed volatility on September 2, with the pharmaceutical sector leading gains, particularly the Hong Kong Stock Connect Medical ETF, which reached a new historical high [1] Group 1: Market Performance - The Hong Kong Stock Connect Medical ETF (159506) rose nearly 2%, achieving a new historical high [1] - Key constituent stocks such as BeiGene and 3SBio increased by over 4%, while WuXi AppTec and Kelun-Bio rose by over 2% [1] Group 2: Company Developments - Heng Rui Medicine announced that it received conditional approval from the National Medical Products Administration for its self-developed innovative drug, SHR2554, which is the first EZH2 inhibitor developed in China [2][3] - The drug targets peripheral T-cell lymphoma (PTCL), which accounts for approximately 25%-30% of non-Hodgkin lymphoma patients in China, with a median onset age of 52 years [3] - Heng Rui's total R&D investment for SHR2554 has reached approximately 21.3 million yuan [3] Group 3: Future Outlook - The first half of 2025 is expected to see explosive growth in the export of Chinese innovative drugs, with significant increases in licensing-out transaction amounts [4] - The Chinese pharmaceutical industry is becoming a major source of global innovative drugs, contributing 50% of new drug molecules entering human clinical trials globally [4] - The Hong Kong Stock Connect Medical ETF focuses on capturing investment opportunities in the pharmaceutical sector, including medical devices, drugs, biotechnology, and medical services [4]